Four cycles of TP (docetaxel for injection, Qilu Pharmaceutical Co. Ltd, National Drug Registration No.: H20031244, 75 mg/m2, intravenous injection; cisplatin for injection [lyophilized], Qilu Pharmaceutical Co. Ltd, National Drug Registration No.: H20023460, 75 mg/m2, intravenous injection) or four cycles of T (docetaxel for injection, Qilu Pharmaceutical Co. Ltd, National Drug Registration No.: H20031244, 100 mg/m2, intravenous injection) were administered before surgery. The post-surgical regimen was four cycles of EC (Epirubicin for injection, Pfizer Pharmaceuticals (Wuxi) Co. Ltd, National Drug Registration No.: H20000497, intravenous injection; Cyclophosphamide for injection, Jiangsu Hengrui Medicine Co. Ltd, National Drug Registration No.: H32026196).
Ge W.K., Yang B., Zuo W.S., Zheng G., Dai Y.Q., Han C., Yang L, & Zheng M.Z. (2015). Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients. Thoracic Cancer, 6(1), 64-69.
+ Open protocol